Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 10/2017

01-10-2017 | Original Article

Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea

Authors: Hyungil Seo, Byong Duk Ye, Eun Mi Song, Sun-Ho Lee, Kiju Chang, Ho-Su Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang

Published in: Digestive Diseases and Sciences | Issue 10/2017

Login to get access

Abstract

Background and Aims

Large-scale studies regarding the long-term outcomes of adalimumab (ADA) treatment in Asian patients with Crohn’s disease (CD) are still scarce.

Methods

We retrospectively analyzed the long-term outcomes of ADA treatment in Korean CD patients who commenced on scheduled ADA treatment at Asan Medical Center between November 2008 and July 2016. Clinical response was defined as maintaining ADA treatment without dose intensification (DI) and/or major abdominal surgery (MAS).

Results

Of the 254 patients who received at least two doses of ADA at 2-week intervals as induction therapy, 250 patients (98.4%) showed an initial favorable response by week 4. Among responders, 243 patients were followed up for longer than 4 weeks and were included for further analysis. The median duration of ADA maintenance therapy was 19.4 months. At the last follow-up, 45 patients (18.5%) required DI after a median of 16.8 months and 31 (12.8%) required MAS after a median of 8.9 months. Finally, 161 patients (66.3%) were still receiving ADA without DI and/or MAS. The cumulative probability of maintaining ADA without DI and/or MAS was 81.1% at 1 year, and 36.5% at 5 years. Secondary loss of response to previous infliximab (P = 0.001) and elevated baseline C-reactive protein at starting ADA treatment (P = 0.008) were identified as independent predictors of a poor response to ADA treatment using multivariate regression analysis.

Conclusions

The long-term outcome of ADA treatment in a real-life cohort of Korean patients with CD appears to be comparable to that reported in previously published Western studies.
Appendix
Available only for authorised users
Literature
1.
2.
Pariente B, Cosnes J, Danese S, et al. Development of the Crohnʼs disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415–1422.CrossRefPubMed
3.
Sandborn WJ, Hanauer S, Van Assche G, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014;8:927–935.CrossRefPubMed
4.
Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.CrossRefPubMed
5.
Park SH, Yang S-K, Park S-K, et al. Long-term prognosis of Crohnʼs disease and its temporal change between 1981 and 2012. Inflamm Bowel Dis. 2014;20:488–494.CrossRefPubMed
6.
Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.CrossRefPubMed
7.
Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239.CrossRefPubMedPubMedCentral
8.
Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.CrossRefPubMed
9.
Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838.CrossRefPubMed
10.
Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628–1640.CrossRefPubMed
11.
Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther. 2009;29:527–534.CrossRefPubMed
12.
Swoger JM, Loftus EV, Tremaine WJ, et al. Adalimumab for Crohns disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010;16:1912–1921.CrossRefPubMed
13.
Chaparro M, Panés J, García V, et al. Long-term durability of response to adalimumab in Crohnʼs disease. Inflamm Bowel Dis. 2012;18:685–690.CrossRefPubMed
14.
Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohns Colitis. 2013;7:154–160.CrossRefPubMed
15.
Peters CP, Eshuis EJ, Toxopeüs FM, et al. Adalimumab for Crohn’s disease: long-term sustained benefit in a population-based cohort of 438 patients. J Crohns Colitis. 2014;8:866–875.CrossRefPubMed
16.
Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease. J Crohns Colitis. 2012;6:160–173.CrossRefPubMed
17.
Watanabe M, Hibi T, Mostafa NM, et al. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn’s disease. J Crohns Colitis. 2014;8:1407–1416.CrossRefPubMed
18.
Ishida K, Inoue T, Fujiwara K, et al. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients. World J Gastroenterol. 2013;19:2676–2682.CrossRefPubMedPubMedCentral
19.
Miyoshi J, Hisamatsu T, Matsuoka K, et al. Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn’s disease. Digestion. 2014;90:130–136.CrossRefPubMed
20.
Chang C-W, Wei S-C, Chou J-W, et al. Safety and efficacy of adalimumab for patients with moderate to severe Crohn’s disease: the Taiwan society of inflammatory bowel disease (TSIBD) study. Intest Res. 2014;12:287–292.CrossRefPubMedPubMedCentral
21.
Sohn IW, Kim ST, Kim B, et al. Efficacy of adalimumab in Korean patients with Crohn’s disease. Gut Liver. 2016;10:255–261.CrossRefPubMed
22.
Takeshima F, Yoshikawa D, Higashi S, et al. Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan. BMC Gastroenterol. 2016;16:82.CrossRefPubMedPubMedCentral
23.
Wu K-C, Ran ZH, Gao X, et al. Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn’s disease. Intest Res. 2016;14:152–163.CrossRefPubMedPubMedCentral
24.
Lee HS, Park SH, Yang SK, et al. Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospital-based cohort study from Korea. J Crohns Colitis. 2015;9:147–155.CrossRefPubMed
25.
Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn’s disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161–1168.CrossRefPubMed
26.
Yang S-K, Hong W-S, Min YI, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986–1997. J Gastroenterol Hepatol. 2000;15:1037–1042.CrossRefPubMed
27.
Yang S-K, Yun S, Kim J-H, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: A KASID study. Inflamm Bowel Dis. 2008;14:542–549.CrossRefPubMed
28.
Park SH, Hwang SW, Kwak MS, et al. Long-term outcomes of infliximab treatment in 582 Korean patients with Crohn’s disease: a hospital-based cohort study. Dig Dis Sci. 2016;61:2060–2067.CrossRefPubMed
29.
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19:5A–36A.CrossRefPubMed
30.
Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106:674–684.CrossRefPubMed
31.
Oussalah A, Babouri A, Chevaux JB, et al. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther. 2009;29:416–423.CrossRefPubMed
32.
33.
Bultman E, de Haar C, van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients. Aliment Pharmacol Ther. 2012;35:335–341.CrossRefPubMed
34.
Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608.CrossRefPubMed
35.
Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33:987–995.CrossRefPubMed
36.
Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40–47.CrossRefPubMed
37.
Oh EH, Ko D-H, Seo H, et al. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol. 2017;23:1489–1496.CrossRefPubMedPubMedCentral
38.
Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OØ, Bendtzen K, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014;20:1714–1721.CrossRefPubMed
39.
Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69:817–821.CrossRefPubMed
40.
Löfberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: results from CARE. Inflamm Bowel Dis. 2012;18:1–9.CrossRefPubMed
41.
Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9:421–427.CrossRef
42.
Kiss LS, Szamosi T, Molnar T, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment Pharmacol Ther. 2011;34:911–922.CrossRefPubMed
43.
Sandborn WJ, Colombel J-F, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011;17:141–151.CrossRefPubMed
44.
Cohen RD, Lewis JR, Turner H, Harrell LE, Hanauer SB, Rubin DT. Predictors of adalimumab dose escalation in patients with Crohnʼs disease at a tertiary referral center. Inflamm Bowel Dis. 2012;18:10–16.CrossRefPubMed
45.
Matsumoto T, Motoya S, Watanabe K, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: a prospective, randomized trial. J Crohns Colitis. 2016;10:1259–1266.CrossRefPubMed
46.
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.CrossRefPubMed
Metadata
Title
Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea
Authors
Hyungil Seo
Byong Duk Ye
Eun Mi Song
Sun-Ho Lee
Kiju Chang
Ho-Su Lee
Sung Wook Hwang
Sang Hyoung Park
Dong-Hoon Yang
Kyung-Jo Kim
Jeong-Sik Byeon
Seung-Jae Myung
Suk-Kyun Yang
Publication date
01-10-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4715-7

Other articles of this Issue 10/2017

Digestive Diseases and Sciences 10/2017 Go to the issue

Review

Strategies to Identify and Reduce Opioid Misuse Among Patients with Gastrointestinal Disorders: A Systematic Scoping Review

Review

Pancreatic Leaks and Fistulae: An Endoscopy-Oriented Classification

Original Article

Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma

Original Article

Microscopic Colitis Evolved Into Inflammatory Bowel Diseases Is Characterized by Increased Th1/Tc1 Cells in Colonic Mucosal Lamina Propria

Original Article

Comparison of ICD-9 Codes for Depression and Alcohol Misuse to Survey Instruments Suggests These Codes Should Be Used with Caution

Original Article

Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits